tiprankstipranks
Trending News
More News >
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
US Market
Advertisement

Contineum Therapeutics, Inc. Class A (CTNM) Stock Forecast & Price Target

Compare
183 Followers
See the Price Targets and Ratings of:

CTNM Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Contineum
Therapeutics, Inc. Class A
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CTNM Stock 12 Month Forecast

Average Price Target

$24.50
▲(144.02% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Contineum Therapeutics, Inc. Class A in the last 3 months. The average price target is $24.50 with a high forecast of $29.00 and a low forecast of $21.00. The average price target represents a 144.02% change from the last price of $10.04.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","23":"$23","30":"$30"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9,16,23,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.96,7.7323076923076925,9.504615384615384,11.276923076923076,13.049230769230768,14.82153846153846,16.593846153846155,18.366153846153846,20.138461538461538,21.91076923076923,23.68307692307692,25.455384615384613,27.22769230769231,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.96,7.386153846153846,8.812307692307693,10.23846153846154,11.664615384615384,13.09076923076923,14.516923076923078,15.943076923076923,17.369230769230768,18.795384615384616,20.22153846153846,21.647692307692306,23.073846153846155,{"y":24.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.96,7.116923076923077,8.273846153846154,9.430769230769231,10.587692307692308,11.744615384615384,12.901538461538461,14.05846153846154,15.215384615384615,16.372307692307693,17.529230769230768,18.686153846153847,19.843076923076925,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.25,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.25,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.25,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.7,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.04,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$29.00Average Price Target$24.50Lowest Price Target$21.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CTNM
Morgan Stanley
Morgan Stanley
$20$21
Buy
109.16%
Upside
Reiterated
08/18/25
Morgan Stanley Reaffirms Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)CTNM.O Contineum Therapeutics Overweight with price target change from 20.00 to 21.00.
William Blair Analyst forecast on CTNM
William Blair
William Blair
Buy
Reiterated
08/06/25
Strategic Focus on PIPE-791 Drives Buy Rating for Contineum Therapeutics
JonesTrading
$23
Buy
129.08%
Upside
Reiterated
08/06/25
Analysts Offer Insights on NA Companies: Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM) and BrightSpring Health Services, Inc. (NASDAQ: BTSG)
Stifel Nicolaus Analyst forecast on CTNM
Stifel Nicolaus
Stifel Nicolaus
$29
Buy
188.84%
Upside
Reiterated
08/06/25
Contineum Therapeutics, Inc. (CTNM, $6.00, Buy; Target $29.00) – 'We're reiterating our Buy rating on CTNM' following the 2Q25 update.
RBC Capital Analyst forecast on CTNM
RBC Capital
RBC Capital
$25
Buy
149.00%
Upside
Reiterated
08/05/25
Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital
Robert W. Baird Analyst forecast on CTNM
Robert W. Baird
Robert W. Baird
$32$16
Buy
59.36%
Upside
Reiterated
03/07/25
Contineum price target lowered to $16 from $32 at BairdContineum price target lowered to $16 from $32 at Baird
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CTNM
Morgan Stanley
Morgan Stanley
$20$21
Buy
109.16%
Upside
Reiterated
08/18/25
Morgan Stanley Reaffirms Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)CTNM.O Contineum Therapeutics Overweight with price target change from 20.00 to 21.00.
William Blair Analyst forecast on CTNM
William Blair
William Blair
Buy
Reiterated
08/06/25
Strategic Focus on PIPE-791 Drives Buy Rating for Contineum Therapeutics
JonesTrading
$23
Buy
129.08%
Upside
Reiterated
08/06/25
Analysts Offer Insights on NA Companies: Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM) and BrightSpring Health Services, Inc. (NASDAQ: BTSG)
Stifel Nicolaus Analyst forecast on CTNM
Stifel Nicolaus
Stifel Nicolaus
$29
Buy
188.84%
Upside
Reiterated
08/06/25
Contineum Therapeutics, Inc. (CTNM, $6.00, Buy; Target $29.00) – 'We're reiterating our Buy rating on CTNM' following the 2Q25 update.
RBC Capital Analyst forecast on CTNM
RBC Capital
RBC Capital
$25
Buy
149.00%
Upside
Reiterated
08/05/25
Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital
Robert W. Baird Analyst forecast on CTNM
Robert W. Baird
Robert W. Baird
$32$16
Buy
59.36%
Upside
Reiterated
03/07/25
Contineum price target lowered to $16 from $32 at BairdContineum price target lowered to $16 from $32 at Baird
Stocks with the Highest Top Analyst Consensus in the General Sector
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Contineum Therapeutics, Inc. Class A

1 Month
xxx
Success Rate
3/4 ratings generated profit
75%
Average Return
+8.60%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +8.60% per trade.
3 Months
xxx
Success Rate
3/4 ratings generated profit
75%
Average Return
+45.67%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +45.67% per trade.
1 Year
Success Rate
4/4 ratings generated profit
100%
Average Return
+70.65%
reiterated a buy rating 18 days ago
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +70.65% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
100%
Average Return
+70.65%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +70.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CTNM Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Aug 25
Strong Buy
7
5
7
4
8
Buy
2
1
1
1
2
Hold
3
1
0
0
0
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
12
8
9
6
10
In the current month, CTNM has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CTNM average Analyst price target in the past 3 months is 24.50.
Each month's total comprises the sum of three months' worth of ratings.

CTNM Financial Forecast

CTNM Earnings Forecast

Next quarter’s earnings estimate for CTNM is -$0.46 with a range of -$0.70 to $0.40. The previous quarter’s EPS was -$0.62. CTNM beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.86% of the time in the same period. In the last calendar year CTNM has Outperformed its overall industry.
Next quarter’s earnings estimate for CTNM is -$0.46 with a range of -$0.70 to $0.40. The previous quarter’s EPS was -$0.62. CTNM beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.86% of the time in the same period. In the last calendar year CTNM has Outperformed its overall industry.
No data currently available

CTNM Sales Forecast

Next quarter’s sales forecast for CTNM is $7.50M with a range of $0.00 to $30.00M. The previous quarter’s sales results were $0.00. CTNM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 50.00% of the time in the same period. In the last calendar year CTNM has Preformed in-line its overall industry.
Next quarter’s sales forecast for CTNM is $7.50M with a range of $0.00 to $30.00M. The previous quarter’s sales results were $0.00. CTNM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 50.00% of the time in the same period. In the last calendar year CTNM has Preformed in-line its overall industry.

CTNM Stock Forecast FAQ

What is CTNM’s average 12-month price target, according to analysts?
Based on analyst ratings, Contineum Therapeutics, Inc. Class A’s 12-month average price target is 24.50.
    What is CTNM’s upside potential, based on the analysts’ average price target?
    Contineum Therapeutics, Inc. Class A has 144.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CTNM a Buy, Sell or Hold?
          Contineum Therapeutics, Inc. Class A has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Contineum Therapeutics, Inc. Class A’s price target?
            The average price target for Contineum Therapeutics, Inc. Class A is 24.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $29.00 ,the lowest forecast is $21.00. The average price target represents 144.02% Increase from the current price of $10.04.
              What do analysts say about Contineum Therapeutics, Inc. Class A?
              Contineum Therapeutics, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of CTNM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis